Laxman Subedi
Overview
Explore the profile of Laxman Subedi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subedi L, Bamjan A, Phuyal S, Shim J, Cho S, Seo J, et al.
J Control Release
. 2024 Dec;
378:637-655.
PMID: 39709071
Type 2 diabetes is a chronic disease characterized by insulin resistance and often worsened by obesity. Effective management involves the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to assist...
2.
Kweon S, Lee J, Yang S, Park S, Subedi L, Shim J, et al.
Biomater Res
. 2023 Sep;
27(1):83.
PMID: 37660070
Background: Despite the effectiveness of glucagon-like peptide-1 agonist (GLP-1A) in the treatment of diabetes, its large molecular weight and high hydrophilicity result in poor cellular permeability, thus limiting its oral...
3.
Pandey P, Kim S, Subedi L, Mujahid K, Kim Y, Cho Y, et al.
J Control Release
. 2023 Mar;
356:507-524.
PMID: 36907564
We developed an orally delivered nanoemulsion that induces cancer immunization. It consists of tumor antigen-loaded nano-vesicles carrying the potent invariant natural killer T-cell (iNKT) activator α-galactosylceramide (α-GalCer), to trigger cancer...
4.
Pulat S, Subedi L, Pandey P, Bhosle S, Hur J, Shim J, et al.
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839662
Atraric acid (AA) is a phenolic compound isolated from that has demonstrated anti-androgen properties and was used to design an alternative formulation for the treatment of alopecia. This new topical...
5.
Subedi L, Pandey P, Khadka B, Shim J, Cho S, Kweon S, et al.
Drug Deliv
. 2022 Nov;
29(1):3397-3413.
PMID: 36419245
Atorvastatin (ATV) has attracted considerable attention as a potential therapeutic agent for cancer because it inhibits cancer cell proliferation by suppressing the mevalonate pathway. However, because of its low oral...
6.
Subedi L, Pandey P, Kang S, Kim K, Cho S, Chang K, et al.
J Control Release
. 2022 Jul;
349:502-519.
PMID: 35835400
In this study, a system for oral delivery of recombinant human parathyroid hormone [rhPTH(1-34); teriparatide (TRP)] was developed to enhance oral absorption and to demonstrate an equivalent therapeutic effect to...
7.
Subedi L, Pandey P, Shim J, Kim K, Cho S, Koo K, et al.
Drug Deliv
. 2022 Jan;
29(1):328-341.
PMID: 35040730
To prepare a topical formulation of bimatoprost (BIM) with high skin permeability, we designed a solvent mixture system composed of ethanol, diethylene glycol monoethyl ether, cyclomethicone, and butylated hydroxyanisole, serving...
8.
Maharjan R, Subedi L, Pangeni R, Jha S, Kang S, Chang K, et al.
Drug Deliv
. 2021 Nov;
28(1):2313-2328.
PMID: 34730056
In this study, we developed oral pemetrexed (PMX) for metronomic dosing to enhance antitumor immunity. PMX was electrostatically complexed with positively charged lysine-linked deoxycholic acid (DL) as an intestinal permeation...
9.
Subedi L, Song S, Jha S, Lee S, Pangeni R, Koo K, et al.
Pharmaceutics
. 2021 Apr;
13(5).
PMID: 33925457
In this study, a stable and highly skin-permeable topical delivery system for itraconazole (ITZ) was designed to provide effective treatment against superficial mycosis. Herein, ITZ was incorporated into a solution...
10.
Pangeni R, Subedi L, Jha S, Kweon S, Kang S, Chang K, et al.
Int J Nanomedicine
. 2020 Oct;
15:7719-7743.
PMID: 33116497
Objective: The anticancer efficacy of orally administered chemotherapeutics is often constrained by low intestinal membrane permeability and oral bioavailability. In this context, we designed a solid oral formulation of oxaliplatin...